Promising Therapies, Treatment Strategies for HR+ Breast Cancer | ASHP Midyear

In the United States, there were 310720 estimated new cases of breast cancer in 2024 and 42250 estimated deaths.¹ Approximately 13.1 percent of women will be diagnosed with breast cancer at some point during their lifetime and nearly 4 million women are currently living with the disease in the US. Although the death rate of breast cancer has continually gone down, the rate of new cases has been slowly increasing.

At the American Society of Health-System Pharmacists 2024 Midyear Clinical Meeting and Exhibition, held December 8 to 12 in New Orleans, Louisiana, Drug Topics sat down with Julia L. Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator of breast medical oncology for the Levine Cancer Institute at Atrium Health, to discuss what emerging therapies or treatment strategies show promise for HR+ breast cancer.

“Things that could be practice changing, certainly the addition of our oral targeted agent for the adjuvant setting,” Ziegengeist said. “Also, maybe incorporating some things in the future related to ctDNA monitoring. For example, if a patient has a mutation that pops up, we can change their treatment earlier on to try to prevent that radiographic progression. Also monitoring for treatment response and progression as well as we move into treatment.”

Follow along with our coverage of the 2024 ASHP Midyear Clinical Meeting and Exhibition here.

Reference

1. Cancer Stat Facts: Female Breast Cancer. Report. NIH. Accessed December 13, 2024. https://seer.cancer.gov/statfacts/html/breast.html